CINXE.COM

<?xml version="1.0" encoding="utf-8"?> <rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Latest posts from BiopharmaTrend.com</title><link>https://www.biopharmatrend.com/blog/</link><description>A fresh look at drug discovery</description><atom:link href="https://www.biopharmatrend.com/rss/" rel="self"></atom:link><language>en-gb</language><lastBuildDate>Wed, 27 Nov 2024 04:11:03 +0000</lastBuildDate><item><title>Trogenix Emerges from Stealth with Precision Gene Therapy Platform to Target Aggressive Cancers</title><link>https://www.biopharmatrend.com/post/1030-trogenix-emerges-from-stealth-with-precision-gene-therapy-platform-to-target-aggressive-cancers/</link><description><a href="https://trogenix.com/">Trogenix Ltd</a><a href="https://www.biospace.com/press-releases/trogenix-unveils-revolutionary-platform-to-transform-cancer-treatment-through-precision-viral-immunotherapy"> has launched</a> its Odysseus platform, leveraging Synthetic Super-Enhancer (SSE) technology to advance precision viral immunotherapy for aggressive cancers.</description><guid>https://www.biopharmatrend.com/post/1030-trogenix-emerges-from-stealth-with-precision-gene-therapy-platform-to-target-aggressive-cancers/</guid></item><item><title>Novartis Expands Radiopharmaceutical Portfolio with $745M Deal with Ratio Therapeutics</title><link>https://www.biopharmatrend.com/post/1029-novartis-expands-radiopharmaceutical-portfolio-with-745m-deal-with-ratio-therapeutics/</link><description><a href="https://www.novartis.com/">Novartis</a> has <a href="https://ratiotx.com/2024/11/18/november-18th-2024-ratio-enters-license-and-collaboration-agreement-with-novartis-for-sstr2-targeting-radiotherapeutic-candidate/">struck a licensing agreement</a> with Boston-based biotech <a href="https://ratiotx.com">Ratio Therapeutics</a>, securing global rights to a promising cancer candidate targeting somatostatin receptor 2 (SSTR2). The deal, announced on November 18, 2024, is valued at up to $745 million, including upfront and potential milestone payments, alongside royalties.</description><guid>https://www.biopharmatrend.com/post/1029-novartis-expands-radiopharmaceutical-portfolio-with-745m-deal-with-ratio-therapeutics/</guid></item><item><title>Immunai and Teva Collaborate to Advance Clinical Trials in Oncology and Immunology</title><link>https://www.biopharmatrend.com/post/1024-immunai-and-teva-collaborate-to-advance-clinical-trials-in-oncology-and-immunology/</link><description>Immunai, an AI-driven biotech company focused on mapping the human immune system, has partnered with Teva Pharmaceuticals in a multi-year collaboration aimed at improving clinical trial outcomes for oncology and immunology therapies.</description><guid>https://www.biopharmatrend.com/post/1024-immunai-and-teva-collaborate-to-advance-clinical-trials-in-oncology-and-immunology/</guid></item><item><title>Medable Adds Generative AI to Simplify and Speed Up Clinical Trials</title><link>https://www.biopharmatrend.com/post/1028-medable-adds-generative-ai-to-simplify-and-speed-up-clinical-trials/</link><description><a href="https://www.biopharmatrend.com/m/company/medable/">Medable Inc</a>. has introduced generative AI capabilities to its Medable Studio platform to streamline and accelerate digital and decentralized clinical trial workflows. The new feature, called Medable AI, simplifies study builds and reduces electronic Clinical Outcome Assessment (eCOA) generation times from days to seconds.</description><guid>https://www.biopharmatrend.com/post/1028-medable-adds-generative-ai-to-simplify-and-speed-up-clinical-trials/</guid></item><item><title>40,000 NHS Healthcare Workers to Get AI Tool That Cuts Admin Time by 80%</title><link>https://www.biopharmatrend.com/post/1027-40000-nhs-healthcare-workers-to-get-ai-tool-that-cuts-admin-time-by-80/</link><description>A new partnership between <a href="https://www.corti.ai/">Corti</a> and <a href="https://www.bighand.com/en-us/">BigHand</a> will bring a specialized AI tool to 40,000 healthcare workers across 76 NHS trusts. The tool is designed to reduce administrative work by up to 80%, giving staff more time to focus on patient care. Corti, founded in 2016, has processed over 100 million patient interactions, refining its AI to suit healthcare environments. BigHand specializes in workflow and documentation tools for healthcare providers, aiming to reduce admin tasks and improve efficiency.</description><guid>https://www.biopharmatrend.com/post/1027-40000-nhs-healthcare-workers-to-get-ai-tool-that-cuts-admin-time-by-80/</guid></item><item><title>Survey Highlights Critical Need for AI Adoption in Regulatory Affairs Amid Unsustainable Workloads</title><link>https://www.biopharmatrend.com/post/1026-survey-highlights-critical-need-for-ai-adoption-in-regulatory-affairs-amid-unsustainable-workloads/</link><description>New research commissioned by <a href="https://www.arisglobal.com/">ArisGlobal</a>, a provider of life sciences technology solutions, reveals that surging regulatory workloads are forcing life sciences companies to prioritize advanced AI adoption in regulatory affairs (RA). The survey, conducted by Censuswide in September 2024, gathered insights from 100 senior regulatory professionals in U.S. pharma and biopharma companies, emphasizing the need for next-generation technology to maintain regulatory compliance and commercial viability.</description><guid>https://www.biopharmatrend.com/post/1026-survey-highlights-critical-need-for-ai-adoption-in-regulatory-affairs-amid-unsustainable-workloads/</guid></item><item><title>What will be the key trends in AI innovation in the Pharmaceutical Industry in 2025?</title><link>https://www.biopharmatrend.com/post/1025-what-will-be-the-key-trends-in-ai-innovation-in-the-pharmaceutical-industry-in-2025/</link><description>The pharmaceutical industry is undergoing transformation thanks to artificial intelligence (AI) in particular GenAI. From drug discovery and manufacturing to speeding up clinical trials and improving sales force effectiveness, AI is reshaping the sector in numerous ways. This trend is set to increase, and the impact of AI will be more pronounced in 2025, enhancing efficiency, reducing costs, and improving patient outcomes.</description><guid>https://www.biopharmatrend.com/post/1025-what-will-be-the-key-trends-in-ai-innovation-in-the-pharmaceutical-industry-in-2025/</guid></item><item><title>Enveda Advances AI-Discovered, Nature-Derived Drug ENV-294 to Phase 1 Trials</title><link>https://www.biopharmatrend.com/post/1023-envedas-ai-discovered-drug-env-294-enters-phase-1-trials-for-eczema/</link><description><a href="https://www.biopharmatrend.com/m/company/enveda-biosciences/">Enveda</a>, a biotechnology company transforming nature&rsquo;s chemistry into medicines using AI, has announced the FDA clearance of an investigational new drug (IND) application for ENV-294. This first-in-class small molecule, designed to treat atopic dermatitis (eczema) and other inflammatory conditions, has now entered Phase 1 clinical trials, with the first patient dosed in late October.</description><guid>https://www.biopharmatrend.com/post/1023-envedas-ai-discovered-drug-env-294-enters-phase-1-trials-for-eczema/</guid></item><item><title>Genesis Therapeutics Collaborates with NVIDIA and Secures Additional NVentures Funding to Accelerate AI-Driven Drug Discovery</title><link>https://www.biopharmatrend.com/post/1022-genesis-therapeutics-collaborates-with-nvidia-and-secures-additional-nventures-funding-to-accelerate-ai-driven-drug-discovery/</link><description><a href="https://genesistherapeutics.ai/">Genesis Therapeutics</a> has announced a collaboration with NVIDIA to advance its AI platform, GEMS (Genesis Exploration of Molecular Space). The partnership is bolstered by an additional equity investment from NVentures, NVIDIA&rsquo;s venture capital arm, following its participation in Genesis&rsquo; <a href="https://www.businesswire.com/news/home/20230821419353/en/Genesis-Therapeutics-Closes-Oversubscribed-200-Million-Series-B">$200 million Series B financing in August 2023</a>.</description><guid>https://www.biopharmatrend.com/post/1022-genesis-therapeutics-collaborates-with-nvidia-and-secures-additional-nventures-funding-to-accelerate-ai-driven-drug-discovery/</guid></item><item><title>Recursion Unveils OpenPhenom-S/16: A Foundation Model for Microscopy Data</title><link>https://www.biopharmatrend.com/post/1021-recursion-unveils-openphenom-s16-a-foundation-model-for-microscopy-data/</link><description><a href="https://www.biopharmatrend.com/m/company/recursion-pharmaceuticals/">Recursion Pharmaceuticals</a>, Inc. (NASDAQ: RXRX) <a href="https://ir.recursion.com/news-releases/news-release-details/recursion-announces-release-openphenom-s16-google-clouds-model">has released</a> <a href="https://www.rxrx.ai/">OpenPhenom-S/16</a>, a new publicly accessible foundation model, on <a href="https://console.cloud.google.com/vertex-ai">Google Cloud&rsquo;s Vertex AI Model Garden</a>. This development marks a meaningful step forward in how life sciences researchers leverage microscopy data for drug discovery and cellular analysis.</description><guid>https://www.biopharmatrend.com/post/1021-recursion-unveils-openphenom-s16-a-foundation-model-for-microscopy-data/</guid></item></channel></rss>